Bioidentical hormones: An evidence-based review for primary care providers

Journal of the American Osteopathic Association

Volumn 111, Issue 3, 2011, Pages 153-164

  Conaway, Eileen ^a  

^a FLORIDA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRIOL; ESTRONE; PRASTERONE; TESTOSTERONE;

CHEMISTRY; EVIDENCE BASED MEDICINE; FEMALE; GENERAL PRACTITIONER; HORMONE SUBSTITUTION; HUMAN; METHODOLOGY; PRIMARY HEALTH CARE; REVIEW; SALIVA; WOMEN'S HEALTH;

DEHYDROEPIANDROSTERONE; ESTRADIOL; ESTRIOL; ESTRONE; EVIDENCE-BASED MEDICINE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PHYSICIANS, PRIMARY CARE; PRIMARY HEALTH CARE; SALIVA; TESTOSTERONE; WOMEN'S HEALTH;

EID: 79954473026     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
2. Strauss J. The synthesis and metabolism of steroid hormones. In: Strauss JF III, Barbieri RL, eds. Yen and Jaffe's Reproductive Endocrinology. 6th ed. Philadelphia, PA: Elsevier; 2009:4.
3. Moskowitz D. A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks. Alt Med Rev. 2006;11(3):208-223.
4. Food and Drug Administration. Bio-identicals: sorting myth from fact. US Food and Drug Administration Web site. http://www.fda.gov/For Consumers/ConsumerUpdates/ucm049311.htm. Updated April 8, 2008. Accessed October 27, 2009.
5. Pharmacy Compounding Compliance Policy Guides Manual. US Food and Drug Administration Web site. http://www.fda.gov/ICECI/Compliance Manuals/CompliancePolicyGuidanceManual/default.htm. Accessed October 30, 2009.
6. American College of Obstetricians and Gynecologists. Compounded bioidentical hormones. ACOG Committee Opinion No. 322. Obstet Gynecol. 2005; 106(1):1139-1140. http://catawbawomenscenter.com/MenopauseACOG Handout.pdf. Accessed October 15, 2009.
7. Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause. 2004;11(3):356-367.
8. Somers S. Ageless: The Naked Truth about Bioidentical Hormones. New York, NY: Crown Publishers; 2006.
9. Kotz D. Why Suzanne Somers loves bioidentical hormones. U.S. News & World Report Health Web site. http://www.usnews.com/health/blogs/onwomen/ 2009/3/25/why-suzanne-somers-loves-bioidentical-hormones.html. Published March 25, 2009. Accessed December 30, 2009.
10. The Basics of Bioidentical Hormone Replacement Therapy. Oprah.com Web site. www.oprah.com/printarticlefull/health/womenshealth/20090112 BHT_FAQ. Accessed October 30, 2009.
11. Women's health connections: it's all about balance. Women's International Pharmacy Web site. http://www.womensinternational.com/all_about_balance. html. Published August 2010. Accessed October 30, 2009.
12. Bio-identical Human Hormone Replacement. University Compounding Pharmacy Web site. https://www.ucprx.com/search/node/estrogen. Accessed October 30, 2009.
13. Galson SK. Pharmacy compounding/compounding of bio-identical hormone replacement therapies: testimony before the Special Committee on Aging, US Senate, April 19, 2007. US Food and Drug Administration Web site. www.fda.gov/NewsEvents/Testimony/ucm154031. Accessed October 30, 2009.
14. Hormone replacement therapy with bioidentical hormones, natural hormone therapy, naturally compounded hormones. Power Surge Web site. http://www.power-surge.com/php/pfp/PFP.php3?file=/usr/local/4admin /apache/vhost/power-surge. Accessed October 30, 2009.
15. Lewis JG, McGill H, Patton VM, Elder PA. Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas. 2002;41(1):1-6.
16. Zava DT, Dollbaum CM, Blen M. Estrogen and progestin bioactivity of foods, herbs, and spices. Proc Soc Exp Biol Med. 1998;217(3):369-378.
17. FDA/CEDR resources. Food and Drug Administration Web site. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed December 30, 2009.
18. Drug information: estradiol. PDR Network Web site. http://www.pdr.net /search/searchResult.aspx?searchCriteria=estradiol. Accessed December 31, 2009.
19. Knuuti J, Kalliokoski R, Janatuinen T, et al. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. Am J Cardiol. 2007;99(12):1648-1652.
20. White WB. Drospirenone with 17β-estradiol in the postmenopausal woman with hypertension. Climacteric. 2007;10(supp 1):25-31.
21. Rosano GM, Gebara O, Sheiban I, et al. Acute administration of 17β- estradiol reduces endothelin-1 release during pacing-induced ischemia. Int J Cardiol. 2007;116(1):34-39.
22. Hillebrand U, Hausberg M, Stock C, et al. 17β-estradiol increases volume, apical surface and elasticity of human endothelium mediated by Na+/H+ exchange. Cardiovasc Res. 2006;69(4):916-924.
23. Yang TS, Chen YJ, Liang WH, et al. A clinical trial of 3 doses of transdermal 17β-estradiol for preventing postmenopausal bone loss: a preliminary study. J Chin Med Assoc. 2007;70(5):200-206.
24. Schaefers M, Muysers C, Alexandersen P, Christiansen C. Effect of microdose transdermal 17β-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial. Menopause. 2009;16(3):559-565.
25. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17β-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA. 2003;290(8):1042-1048.
26. Dhir A, Kulkarni SK. Antidepressant-like effect of 17β-estradiol: involvement of dopaminergic, serotonergic, and (or) sigma-1 receptor systems. Can J Physiol Pharmacol. 2008;86(10):726-735.
27. Mannino CA, South SM, Quinones-Jenab V, Inturrisi CE. Estradiol replacement in ovariectomized rats is antihyperalgesic in the formalin test. J Pain. 2007;8(4):334-342.
28. Alonso A, Fernández R, Moreno M, et al. Positive effects of 17β-estradiol on insulin sensitivity in aged ovariectomized female rats. J Gerontol A Biol Sci Med Sci. 2006;61(5):419-426.
29. Hogue CW, Freedlang K, Hershey T, et al. Neurocognitive outcomes are not improved by 17β-estradiol in postmenopausal women undergoing cardiac surgery. Stroke. 2007;38(7):2048-2054.
30. Wood CE, Clarkson TB, Chen H, et al. Comparative effects of oral conjugated equine estrogens and micronized 17β-estradiol on breast proliferation: a retrospective analysis. Menopause. 2008;15(5):890-898.
31. van Haaften M, Donker GH, Sie-Go DM, Haspels AA, Thijssen JH. Biochemical and histological effects of vaginal estriol and estradiol applications on the endometrium, myometrium and vagina of postmenopausal women. Gynecol Endocrinol. 1997;11(3):175-185.
32. Nahoul K, Dehennin L, Jondet M, Roger M. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas. 1993;16(3):185-202.
33. Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007;109(3):588-596.
34. Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17β-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007;110(4):771-779.
35. Kicovic PM, Cortes-Prieto J, Milojevic S, Haspels AA, Aljinovic A. The treatment of postmenopausal vaginal atrophy with Oventin vaginal cream or suppositories: clinical, endocrinological and safety aspects. Maturitas. 1980;2(4):275-282.
36. Tzingounis VA, Aksu MF, Greenblatt RB. Estriol in the management of the menopause. JAMA. 1978;239(16):1638-1641.
37. Kupperman HS, Wetchler BB, Blatt MH. Contemporary therapy of the menopausal syndrome. JAMA. 1959;171(12):1627-1637.
38. Yang TS, Tsan SH, Chang SP, Ng HT. Efficacy and safety of estriol replacement therapy for climacteric women. Chin Med J (Taipei). 1999;55(5):386-391.
39. Head KA. Estriol: safety and efficacy. Alt Med Rev. 1998;3(2):101-113.
40. Takahashi K, Manabe A, Okada M, Kurioka H, Kanasaki H, Miyazaki K. Efficacy and safety of oral estriol for managing postmenopausal symptoms. Maturitas. 2000;34(2):169-177.
41. Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol. 2002;52(4):421-428.
42. Granberg S, Ylöstalo P, Wilkand M, Karlsson B. Endometrial sonographic and histologic findings in women with and without hormonal replacement therapy suffering from postmenopausal bleeding. Maturitas. 1997;27(1):35- 40.
43. Granberg S, Eurenius K, Lindgren R, Wilhelmsson L. The effects of oral estriol on the endometrium in postmenopausal women. Maturitas. 2002;42(2):149- 156.
44. Drug Information: Prometrium. CenterWatch Web site. http://www.centerwatch. com/drug-information/fda-approvals/drug-details.aspx?DrugID=438. Accessed December 30, 2009
45. Desreux J, Kebers F, Noël A, et al. Progesterone receptor activation: an alternative to SERMs in breast cancer. Eur J Cancer. 2000;36(supp 4):90-91
46. Wright DW, Kellermann AL, Hertzberg VS, et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med. 2007;49(4):391-402.e2.
47. Vashisht A, Wadsworth F, Carey A, Carey B, Studd J. A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen. Gynecol Endocrinol. 2005;21(2):101-105.
48. Hermann AC, Nafziger AN, Victory J, Kulawy R, Rocci ML Jr, Bertino JS Jr. Over-the-counter progesterone cream produces significant drug exposure compared to a Food and Drug Administration-approved oral progesterone product. J Clin Pharmacol. 2005; 45(6):614-619.
49. Davis SR, Moreau M, Kroll R, et al; for the APHRODITE Study Team. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008;359(19):2005-2017.
50. Ness RB, Albano JD, McTiernan A, Cauley JA. Influence of estrogen plus testosterone supplementation on breast cancer. Arch Intern Med. 2009;169(1): 1-46.
51. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined strogen and testosterone use and risk of breast cancer in postmenopausal omen. Arch Intern Med. 2006;166(14):1483-1489.
52. Zang H, Sahlin L, Masironi B, Eriksson E, Hirschberg AL. Effect of testosterone reatment on endometrial proliferation in postmenopausal women. Clin Endocrinol Metab. 2007;92(6): 2169-2175.
53. Jankowski CM, Gozansky WS, Schwartz RS. Effects of dehydroepiandrosterone eplacement therapy on bone mineral density in older adults: a randomized, ontrolled trial. J Clin Endocrinol Metab. 2006;91(8):2986-2993.
54. Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment or sexual function, well-being, and menopausal symptoms in postmenopausal omen with low libido. J Sex Med. 2009;6(9):2579-2590.
55. Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009;16(5):923-931.
56. Calvo E, Luu-The W, Morissette J, et al. Pangenomic changes induced by DHEA in the skin of postmenopausal women. J Steroid Biochem Mol Biol. 2008;112(4-5):186-193.
57. Panjari M, Bell RJ, Jane F, Adams J, Morrow C, Davis SR. The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas. 2009; 63(3):240-245.
58. Parsons TD, Kratz KM, Thompson E, et al. DHEA supplementation and cognition in postmenopausal women. Int J Neurosci. 2006;116(2):141-155.
59. Løkkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard Ø. Hormone therapy and risk of myocardialinfarction: a national register study. Eur Heart J. 2008;29(21):2660-2668.
60. ACOG Committee on Gynecologic Practice. ACOG Committee Opinion #322: compounded bioidentical hormones. Obstet Gynecol. 2005;106(5 pt 1):1139- 1140.
61. AMA HOD Reaffirms Society's Position on Bioidentical Hormones [press release]. Chevy Chase, MD: The Endocrine Society; July 2009. http://www.endosociety. org/advocacy/insider/AMAReaffirmsTES.cfm. Accessed January 1, 2010.
62. The Endocrine Society. Position Statement: Bioidentical Hormones 2006. Chevy Chase, MD: The Endocrine Society; July 2009. http://www.endosociety. org/advocacy/policy/upload/BH_position_Statement_final_10_25_06_w_ Header.pdf Accessed March 1, 2011.
63. US Preventive Services Task Force. Hormone replacement therapy for the prevention of chronic diseases in postmenopausal women. May 2005. www.uspreventiveservicestaskforce.org/uspstf/uspspmho.htm#summary. Accessed October 27, 2009.
64. Utian RH, Archer DF, Bachmann GA, et al; and the North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause. 2008;15(4 pt 1):584-602.
65. Bioidentical hormones. ClinicalTrials.gov. US National Institutes of Health Web site. http://clinicaltrials.gov/ct2/results?term=bioidentical+hormones. Accessed January 1, 2010.